PT-141 (Bremelanotide)

PT-141 (Bremelanotide) FDA-Approved Off-Label for Men

Brand: Vyleesi
Category: Sexual Health — Melanocortin-4 Receptor Agonist

How it works. PT-141, also known as bremelanotide, is a melanocortin-4 receptor agonist. Unlike PDE5 inhibitors such as sildenafil or tadalafil, which work by enhancing blood flow through nitric oxide pathways in vascular smooth muscle, bremelanotide works centrally through melanocortin pathways in the brain related to sexual desire and arousal. That mechanistic difference matters clinically: a patient with pure vascular erectile dysfunction may do fine with a PDE5 inhibitor, while a patient whose problem is low desire, arousal disconnect, or central sexual motivation may not respond to blood-flow drugs at all. That is where PT-141 has its niche.

Why a physician prescribes it. Bremelanotide is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women—a very specific indication. Use in men, postmenopausal women, or any sexual dysfunction context outside that label is off-label and must be documented as such, with a clear patient-specific rationale. In men with normal erectile function but low libido, in postmenopausal women with desire changes, or in men who have failed PDE5 inhibitors, off-label discussion may be reasonable when other causes have been evaluated.

Cautions and side effects. Bremelanotide can cause transient blood-pressure increases and heart-rate decreases that matter in patients with unstable cardiovascular status. Uncontrolled hypertension is a contraindication. The FDA-approved dosing limit is no more than eight doses per month, and that limit exists for a reason—dose escalation should not be casual. Nausea is the most common adverse effect (roughly 40% in trials), followed by flushing (~20%) and headache (~11%). Focal hyperpigmentation has been reported with repeated use. Alcohol interaction is significant, so patients are counseled to avoid use within 24 hours of drinking.